Instil Bio Inc. (TIL) - Total Assets
Based on the latest financial reports, Instil Bio Inc. (TIL) holds total assets worth $200.43 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See debt-free asset ratio of Instil Bio Inc. to measure how much of total assets are equity-financed.
Instil Bio Inc. - Total Assets Trend (2019–2025)
This chart illustrates how Instil Bio Inc.'s total assets have evolved over time, based on quarterly financial data. Explore Instil Bio Inc. (TIL) investment intensity to see how much of total assets are deployed in long-term investments.
Instil Bio Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Instil Bio Inc.'s total assets of $200.43 Million consist of 94.1% current assets and 5.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.3% |
| Accounts Receivable | $848.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Instil Bio Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Instil Bio Inc..
Key Asset Composition Facts
- Current vs. Non-Current Assets: Instil Bio Inc.'s current assets represent 94.1% of total assets in 2025, a decrease from 98.0% in 2019.
- Cash Position: Cash and equivalents constituted 3.3% of total assets in 2025, down from 93.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Instil Bio Inc. Competitors by Total Assets
Key competitors of Instil Bio Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Instil Bio Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 39.87 | 30.33 | 24.09 |
| Quick Ratio | 39.87 | 30.33 | 24.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $183.58 Million | $212.03 Million | $550.62 Million |
Instil Bio Inc. - Advanced Valuation Insights
This section examines the relationship between Instil Bio Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.49 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -22.8% |
| Total Assets | $203.52 Million |
| Market Capitalization | $51.27 Million USD |
Valuation Analysis
Below Book Valuation: The market values Instil Bio Inc.'s assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Instil Bio Inc.'s assets decreased by 22.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Instil Bio Inc. (2019–2025)
The table below shows the annual total assets of Instil Bio Inc. from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $203.52 Million | -22.78% |
| 2024-12-31 | $263.57 Million | -19.06% |
| 2023-12-31 | $325.63 Million | -32.46% |
| 2022-12-31 | $482.13 Million | -20.96% |
| 2021-12-31 | $609.98 Million | +91.21% |
| 2020-12-31 | $319.01 Million | +3266.53% |
| 2019-12-31 | $9.48 Million | -- |
About Instil Bio Inc.
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.